| Not Yet Recruiting | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT NCT07302776 | Stanford University | Phase 1 |
| Not Yet Recruiting | Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) NCT06995521 | Sung Won Choi | Phase 2 |
| Recruiting | Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation NCT06590285 | Scripps Health | N/A |
| Not Yet Recruiting | Autologous Serum Obtained by a Closed-Circuit Collection Device NCT07014059 | GIANCARLO FATOBENE | Phase 2 |
| Recruiting | Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD). NCT07314892 | Medical University of Gdansk | — |
| Not Yet Recruiting | Safety and Efficacy of Treg Cell in the Treatment of GVHD NCT06411184 | Xuzhou Medical University | Phase 1 / Phase 2 |
| Recruiting | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transpla NCT06462365 | Tr1X, Inc. | Phase 1 |
| Unknown | Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT NCT06334367 | Wang Xin | Phase 2 |
| Not Yet Recruiting | Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Ac NCT06083129 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Al NCT05544448 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis NCT06000982 | Shanghai Jiao Tong University School of Medicine | Phase 3 |
| Not Yet Recruiting | MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib NCT06075225 | Sichuan University | Phase 2 |
| Completed | Effect of PMSCs and Their Secretome for the Treatment of GvHD NCT06469411 | Tabriz University of Medical Sciences | Phase 3 |
| Recruiting | A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Ce NCT05675930 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) NCT05415410 | VectivBio AG | Phase 2 |
| Terminated | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus H NCT05263999 | Equillium | Phase 3 |
| Unknown | Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD NCT05094765 | Shenzhen Xbiome Biotech Co., Ltd. | EARLY_Phase 1 |
| Unknown | Outcomes of Patients After Allo-HSCT With Decitabine and NAC NCT04945096 | The First Affiliated Hospital of Soochow University | Phase 3 |
| Completed | Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing NCT07508345 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Completed | Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911 | Zachariah Michael DeFilipp | Phase 1 |
| Completed | The Safety and Efficacy of Fecal Microbiota Transplant (FMT) for Steroid-refractory Graft-versus-host Disease NCT06938165 | Nanfang Hospital, Southern Medical University | N/A |
| Completed | Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation NCT03680092 | Dimitrios Tzachanis, MD PhD | Phase 2 |
| Withdrawn | Allogeneic Skin Grafting NCT04015947 | University of Minnesota | N/A |
| Completed | A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD NCT03763318 | Equillium | Phase 1 / Phase 2 |
| Completed | High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Dise NCT03945591 | NYU Langone Health | Phase 2 |
| Completed | Itacitinib for Low Risk GVHD NCT03846479 | John Levine | Phase 2 |
| Completed | CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease NCT03605927 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD NCT03459040 | John Levine | Phase 2 |
| Completed | α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression NCT03188601 | Rambam Health Care Campus | — |
| Completed | A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression NCT02891603 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT NCT02942173 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 / Phase 3 |
| Completed | Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients NCT02712762 | Singapore National Eye Centre | — |
| Completed | Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention NCT02588339 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Comparison of Two Automated Mononuclear Collection Systems in Patients Undergoing Extracorporeal Photochemothe NCT02490163 | Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 3 |
| Terminated | Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation NCT02338232 | Hackensack Meridian Health | N/A |
| Completed | Immuno-regulatory Profiling of T Cells in GVHD Treated With Extracorporeal Photopheresis NCT03851601 | Henry Ford Health System | — |
| Completed | Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation NCT03233659 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Completed | Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients NCT02156479 | Lophius Biosciences GmbH | — |
| Completed | 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014 NCT02441075 | Nationwide Children's Hospital | N/A |
| Completed | IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD NCT02066051 | Mayo Clinic | N/A |
| Terminated | Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) NCT01940796 | Massachusetts General Hospital | Phase 1 |
| Unknown | Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic G NCT01549665 | Samsung Medical Center | Phase 1 / Phase 2 |
| Completed | Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) NCT01295710 | Neovii Biotech | Phase 3 |
| Completed | Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplan NCT00282282 | Dana-Farber Cancer Institute | Phase 2 |